N5334 FINAL ACCURATE ANSWERS
LATEST EDITION GUARANTEED A+
2025/2026
Prescribing |basics |- |ANS-Prescribing |is |regulated |by |state |BON
Proper |RX |- |ANS-Providers |name |and |address, |Telephone
DEA
Pt |name/DOB/Addres
Name |of |Drug, |strength, |SIG(directions) |with |indication/Route |and |frequency, |Quantity |and |signature.
Drug |Schedules: |Most |addictive |to |least |- |ANS-1: |Heroin,LSD, |MJ
2: |hydrocodone, |cocaine, |Methamphetamine, |methadone, |oxycodone, |meperidine, |fentanyl, |adderall,
|ritalin
3: |codeine, |ketamine, |testosterone
4: |xanax, |valium, |soma, |ambient, |tramadol
5: |antidiarrheal, |antitussives, |lomotil, |lyrica
Pharmicodyamics |- |ANS-The |effects |of |drug |on |the |body. |Receptors |are |large |molecules |usually
|proteins, |that |interact |and |mediate |the |action |of |drugs
agonist |- |ANS-produce |receptor |stimulation |and |a |conformational |change |every |time |they |bind. |Do
|not |need |all |available |receptors |to |produce |a |maximum |response
Partial |agonist |- |ANS-drugs |that |have |properties |in |b/w |those |of |full |agonist |and |antagonist. |They
|bind |to |receptors |but |when |they |occupy |the |receptor |sites, |they |stimulate |only |some |of |the
|receptors.
,antagonist |- |ANS-drugs |with |affinity |for |a |receptor |but |with |no |intrinsic |activity. |Affinity |allows |the
|antagonist |to |bind |to |receptors, |but |lack |of |intrinsic |activity |prevents |the |bound |antagonist |from
|causing |receptor |activation. |The |block |action |of |drugs |(ex. |Narcan)
Bioavailabity |- |ANS-% |of |administered |dosage |of |the |drug |that |survives |the |first |pass |through |the |liver
|and |reaches |the |blood |stream
half |life |- |ANS-Time |required |for |the |amount |of |a |drug |in |the |body |to |decline |by |50%, |drugs |with
|shorter |half |lives |must |be |administer |frequently. |4.5-5.5 |times |the |half |life |to |get |steady |state |and |to
|be |limited |from |the |body
what |the |body |does |to |the |drug |- |ANS-absorption, |distribution, |metabolism, |excretion
Distribution |- |ANS-movement |of |absorbed |drug |in |bodily |fluids |throughout |the |body |to |target |tissue.
|Properties |affecting: |lipid/water |solubility, |PH |affects |ionization |of |drug, |protein |binding, |size |of
|molecule |(smaller |molecules |are |more |able |to |diffuse)
Tissue: |fat, |bone, |blood/brain |barrier |(only |lipid |soluble |will |pass), |placental |barrier |(many |drugs |can
|pass)
Protein |binding |- |ANS-unbound |drug |is |free |which |is |active, |crosses |membrane. |Low |plasma |proteins
|result |in |more |free |drug. |Competition: |when |2 |highly |bound |drugs |are |given |it |increases |the |level |of
|both |drugs
Metabolism |- |ANS-take |place |in |the |liver |mostly. |Chemical |change |of |a |drug |structure |to: |
Enhance |excretion, |inactivate |the |drug, |increase |therapeutic |action, |active |a |prodrug |(inactive |until
|metabolized |in |the |body |into |the |active |compound, |ex: |levodopa), |increase |or |decrease |toxicity
CYP450 |- |ANS-enzymes |constitutes |the |most |important |of |the |phase |I |metabolizing |enzymes |(account
|for |about |75% |of |drug |metabolism |in |the |liver)
Phase |2: |conjugation |reaction |occur |leading |to |large |increases |in |hydrophilicity |of |the |substrates
|rendering |them |more |readily |excretable
,Substrate |- |ANS-an |agent |that |is |metabolized |by |an |enzyme |into |a |metabolite |and |product |and
|eventually |excreted
Inhibitors |- |ANS-compete |with |other |drugs |for |a |particular |enzyme |affecting |the |metabolism
|(decreased) |of |the |substrate |and |decreases |the |excretion |of |the |substrate |and |increasing |the
|circulating |drug
inducer |- |ANS-competes |with |other |drugs |for |a |particular |enzyme |affecting |metabolism |of |the
|substrate |(increases) |decreasing |the |efficacy |of |the |drug
excretion |- |ANS-renal: |passive |glomerular |filtration, |active |tubular |secretion, |tubular |reabsorption, |gi
|tract, |lung, |sweat |and |salivary, |mammary
genomics |- |ANS-study |of |the |complete |set |of |genetic |information |present |in |a |cell, |an |organism, |or
|species
pharmacogenetics |- |ANS-the |study |of |the |influence |of |hereditary |factors |on |the |response |of |individual
|organisms |to |drugs, |and |the |study |of |variations |of |DNA |and |RNA |characteristics |as |related |to |drug
|response
Pharmacogenetics |tests |- |ANS-Mentioned |on |drug |labels |can |be |classified |as |"test |required," |"test
|recommended," |and |"information |only." |Currently, |four |drugs |are |required |to |have |pharmacogenetics
|testing |performed |before |they |are |prescribed: |cetuximab, |trastuzumab, |maraviroc |and |dasatinib
wafarin, |carbamazepine, |valproic |acid |and |abacavir |are |recommended |to |tests |prior |to |initial |dosing
Carbamazepine |and |Asisans |- |ANS-Initiating |carbamazepine |therapy |in |these |patients |(allele |HLA-
B*1502) |are |at |high |risk |for |developing |Steven |Johnson |syndrome |or |toxic |epidermal |necrolysis |(TEN)
The |ability |of |the |anesthetic |to |penetrate |the |axon |membrane |is |determined |by |3 |properties. |What
|are |they? |- |ANS-Molecular |size, |Lipid |solubility, |degree |of |ionization |at |tissue |pH
, Why |is |epinephrine |given |with |local |anesthetics? |- |ANS-Decreases |local |blood |flow |(decreased |risk |of
|bleeding)
Delays |systemic |absorption |of |the |anesthetic
prolongs |anesthesia
reduces |the |risk |of |toxicity
What |is |the |most |widely |used |local |anesthetic? |- |ANS-Lidocaine
What |is |a |possible |fatal |reaction |to |benzocaine |- |ANS-Methemoglobinemia
What |is |included |in |application |guidelines |for |topical |anesthetics |- |ANS-avoid |wrapping |the |site |and
|heating |the |site, |avoid |application |to |open |skin
Which |medication |will |not |cause |rebound |headaches |from |overuse? |- |ANS-propranolol |(preventative)
What |is |the |best |option |for |menstural |migraine? |- |ANS-low |dose |estrogen |about |3 |days |prior |to
|menses
What |food |can |trigger |migraines? |- |ANS-Hot |dog |d/t |nitrates
What |medication |is |a |Seratonin |1B1D |receptor |agonist? |- |ANS-Sumatriptan
Butterbur |can |help |as |prevention |for |migraine |therapy. |What |side |effect |can |occur? |- |ANS-Liver
|damage
What |are |the |3 |main |classes |of |opiod |receptors? |- |ANS-Mu |kappa |delta
Which |of |the |following |will |reserve |he |effects |caused |by |opioid |agonist? |- |ANS-naloxone
Which |of |the |medications |are |used |to |treat |OIC? |- |ANS-Naloxegol, |methylinaltrexone, |lubiprostone
LATEST EDITION GUARANTEED A+
2025/2026
Prescribing |basics |- |ANS-Prescribing |is |regulated |by |state |BON
Proper |RX |- |ANS-Providers |name |and |address, |Telephone
DEA
Pt |name/DOB/Addres
Name |of |Drug, |strength, |SIG(directions) |with |indication/Route |and |frequency, |Quantity |and |signature.
Drug |Schedules: |Most |addictive |to |least |- |ANS-1: |Heroin,LSD, |MJ
2: |hydrocodone, |cocaine, |Methamphetamine, |methadone, |oxycodone, |meperidine, |fentanyl, |adderall,
|ritalin
3: |codeine, |ketamine, |testosterone
4: |xanax, |valium, |soma, |ambient, |tramadol
5: |antidiarrheal, |antitussives, |lomotil, |lyrica
Pharmicodyamics |- |ANS-The |effects |of |drug |on |the |body. |Receptors |are |large |molecules |usually
|proteins, |that |interact |and |mediate |the |action |of |drugs
agonist |- |ANS-produce |receptor |stimulation |and |a |conformational |change |every |time |they |bind. |Do
|not |need |all |available |receptors |to |produce |a |maximum |response
Partial |agonist |- |ANS-drugs |that |have |properties |in |b/w |those |of |full |agonist |and |antagonist. |They
|bind |to |receptors |but |when |they |occupy |the |receptor |sites, |they |stimulate |only |some |of |the
|receptors.
,antagonist |- |ANS-drugs |with |affinity |for |a |receptor |but |with |no |intrinsic |activity. |Affinity |allows |the
|antagonist |to |bind |to |receptors, |but |lack |of |intrinsic |activity |prevents |the |bound |antagonist |from
|causing |receptor |activation. |The |block |action |of |drugs |(ex. |Narcan)
Bioavailabity |- |ANS-% |of |administered |dosage |of |the |drug |that |survives |the |first |pass |through |the |liver
|and |reaches |the |blood |stream
half |life |- |ANS-Time |required |for |the |amount |of |a |drug |in |the |body |to |decline |by |50%, |drugs |with
|shorter |half |lives |must |be |administer |frequently. |4.5-5.5 |times |the |half |life |to |get |steady |state |and |to
|be |limited |from |the |body
what |the |body |does |to |the |drug |- |ANS-absorption, |distribution, |metabolism, |excretion
Distribution |- |ANS-movement |of |absorbed |drug |in |bodily |fluids |throughout |the |body |to |target |tissue.
|Properties |affecting: |lipid/water |solubility, |PH |affects |ionization |of |drug, |protein |binding, |size |of
|molecule |(smaller |molecules |are |more |able |to |diffuse)
Tissue: |fat, |bone, |blood/brain |barrier |(only |lipid |soluble |will |pass), |placental |barrier |(many |drugs |can
|pass)
Protein |binding |- |ANS-unbound |drug |is |free |which |is |active, |crosses |membrane. |Low |plasma |proteins
|result |in |more |free |drug. |Competition: |when |2 |highly |bound |drugs |are |given |it |increases |the |level |of
|both |drugs
Metabolism |- |ANS-take |place |in |the |liver |mostly. |Chemical |change |of |a |drug |structure |to: |
Enhance |excretion, |inactivate |the |drug, |increase |therapeutic |action, |active |a |prodrug |(inactive |until
|metabolized |in |the |body |into |the |active |compound, |ex: |levodopa), |increase |or |decrease |toxicity
CYP450 |- |ANS-enzymes |constitutes |the |most |important |of |the |phase |I |metabolizing |enzymes |(account
|for |about |75% |of |drug |metabolism |in |the |liver)
Phase |2: |conjugation |reaction |occur |leading |to |large |increases |in |hydrophilicity |of |the |substrates
|rendering |them |more |readily |excretable
,Substrate |- |ANS-an |agent |that |is |metabolized |by |an |enzyme |into |a |metabolite |and |product |and
|eventually |excreted
Inhibitors |- |ANS-compete |with |other |drugs |for |a |particular |enzyme |affecting |the |metabolism
|(decreased) |of |the |substrate |and |decreases |the |excretion |of |the |substrate |and |increasing |the
|circulating |drug
inducer |- |ANS-competes |with |other |drugs |for |a |particular |enzyme |affecting |metabolism |of |the
|substrate |(increases) |decreasing |the |efficacy |of |the |drug
excretion |- |ANS-renal: |passive |glomerular |filtration, |active |tubular |secretion, |tubular |reabsorption, |gi
|tract, |lung, |sweat |and |salivary, |mammary
genomics |- |ANS-study |of |the |complete |set |of |genetic |information |present |in |a |cell, |an |organism, |or
|species
pharmacogenetics |- |ANS-the |study |of |the |influence |of |hereditary |factors |on |the |response |of |individual
|organisms |to |drugs, |and |the |study |of |variations |of |DNA |and |RNA |characteristics |as |related |to |drug
|response
Pharmacogenetics |tests |- |ANS-Mentioned |on |drug |labels |can |be |classified |as |"test |required," |"test
|recommended," |and |"information |only." |Currently, |four |drugs |are |required |to |have |pharmacogenetics
|testing |performed |before |they |are |prescribed: |cetuximab, |trastuzumab, |maraviroc |and |dasatinib
wafarin, |carbamazepine, |valproic |acid |and |abacavir |are |recommended |to |tests |prior |to |initial |dosing
Carbamazepine |and |Asisans |- |ANS-Initiating |carbamazepine |therapy |in |these |patients |(allele |HLA-
B*1502) |are |at |high |risk |for |developing |Steven |Johnson |syndrome |or |toxic |epidermal |necrolysis |(TEN)
The |ability |of |the |anesthetic |to |penetrate |the |axon |membrane |is |determined |by |3 |properties. |What
|are |they? |- |ANS-Molecular |size, |Lipid |solubility, |degree |of |ionization |at |tissue |pH
, Why |is |epinephrine |given |with |local |anesthetics? |- |ANS-Decreases |local |blood |flow |(decreased |risk |of
|bleeding)
Delays |systemic |absorption |of |the |anesthetic
prolongs |anesthesia
reduces |the |risk |of |toxicity
What |is |the |most |widely |used |local |anesthetic? |- |ANS-Lidocaine
What |is |a |possible |fatal |reaction |to |benzocaine |- |ANS-Methemoglobinemia
What |is |included |in |application |guidelines |for |topical |anesthetics |- |ANS-avoid |wrapping |the |site |and
|heating |the |site, |avoid |application |to |open |skin
Which |medication |will |not |cause |rebound |headaches |from |overuse? |- |ANS-propranolol |(preventative)
What |is |the |best |option |for |menstural |migraine? |- |ANS-low |dose |estrogen |about |3 |days |prior |to
|menses
What |food |can |trigger |migraines? |- |ANS-Hot |dog |d/t |nitrates
What |medication |is |a |Seratonin |1B1D |receptor |agonist? |- |ANS-Sumatriptan
Butterbur |can |help |as |prevention |for |migraine |therapy. |What |side |effect |can |occur? |- |ANS-Liver
|damage
What |are |the |3 |main |classes |of |opiod |receptors? |- |ANS-Mu |kappa |delta
Which |of |the |following |will |reserve |he |effects |caused |by |opioid |agonist? |- |ANS-naloxone
Which |of |the |medications |are |used |to |treat |OIC? |- |ANS-Naloxegol, |methylinaltrexone, |lubiprostone
